NCT03370263View on ClinicalTrials.gov

BENLYSTA® Special Drug Use Investigation

RecruitingOBSERVATIONAL

Enrollment

600

Participants

Timeline

Start Date

January 15, 2018

Primary Completion Date

June 26, 2025

Study Completion Date

June 26, 2025

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

Benlysta

Benlysta will be administered intravenously or subcutaneously.

Trial Locations (1)

730-0001

RECRUITING

GSK Investigational Site, Hiroshima

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT03370263 - BENLYSTA® Special Drug Use Investigation | Biotech Hunter | Biotech Hunter